Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

6WZL

LY3041658 Fab bound to CXCL7

6WZL の概要
エントリーDOI10.2210/pdb6wzl/pdb
関連するPDBエントリー6WZJ 6WZK
分子名称LY3041658 Fab heavy chain, LY3041658 Fab light chain, C-X-C motif chemokine 7, ... (6 entities in total)
機能のキーワードcxcr1, cxcr2, neutrophil, nap-2, immune system
由来する生物種Homo sapiens
詳細
タンパク質・核酸の鎖数6
化学式量合計110989.29
構造登録者
Durbin, J.D.,Druzina, Z. (登録日: 2020-05-14, 公開日: 2020-11-25, 最終更新日: 2024-11-06)
主引用文献Boyles, J.S.,Beidler, C.B.,Strifler, B.A.,Girard, D.S.,Druzina, Z.,Durbin, J.D.,Swearingen, M.L.,Lee, L.N.,Kikly, K.,Chintharlapalli, S.,Witcher, D.R.
Discovery and characterization of a neutralizing pan-ELR+CXC chemokine monoclonal antibody.
Mabs, 12:1831880-1831880,
Cited by
PubMed Abstract: CXCR1 and CXCR2 signaling play a critical role in neutrophil migration, angiogenesis, and tumorigenesis and are therefore an attractive signaling axis to target in a variety of indications. In human, a total of seven chemokines signal through these receptors and comprise the ELRCXC chemokine family, so named because of the conserved ELRCXC N-terminal motif. To fully antagonize CXCR1 and CXCR2 signaling, an effective therapeutic should block either both receptors or all seven ligands, yet neither approach has been fully realized clinically. In this work, we describe the generation and characterization of LY3041658, a humanized monoclonal antibody that binds and neutralizes all seven human and cynomolgus monkey ELRCXC chemokines and three of five mouse and rat ELRCXC chemokines with high affinity. LY3041658 is able to block ELRCXC chemokine-induced Ca mobilization, CXCR2 internalization, and chemotaxis as well as neutrophil mobilization without affecting other neutrophil functions. In addition to the and activity, we characterized the epitope and structural basis for binding in detail through alanine scanning, crystallography, and mutagenesis. Together, these data provide a robust preclinical characterization of LY3041658 for which the efficacy and safety is being evaluated in human clinical trials for neutrophilic skin diseases.
PubMed: 33183151
DOI: 10.1080/19420862.2020.1831880
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.29 Å)
構造検証レポート
Validation report summary of 6wzl
検証レポート(詳細版)ダウンロードをダウンロード

227344

件を2024-11-13に公開中

PDB statisticsPDBj update infoContact PDBjnumon